Current understanding of the role of PPAR γ in gastrointestinal cancers

PPAR Research

Volumn , Issue , 2009, Pages

  Qiao, Liang ^a   Zou, Bing ^a,b   Wong, Benjamin C Y ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BEXAROTENE; BEZAFIBRATE; CAPECITABINE; CS 7017; CYCLOPENTONE 15 DEOXY E12 14 PROSTAGLANDIN J2; EPIDERMAL GROWTH FACTOR; ETALOCIB; FIBROBLAST GROWTH FACTOR; HEME OXYGENASE 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IRINOTECAN; LSN 862; MESALAZINE; MITOGEN ACTIVATED PROTEIN KINASE; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PROSTAGLANDIN J2; PROSTAGLANDIN SYNTHASE; RADIOACTIVE IODINE; ROFECOXIB; ROSIGLITAZONE; SOMATOMEDIN; SPIROLAXINE; TEMOZOLOMIDE; TROGLITAZONE; TYROSINE KINASE RECEPTOR; TZD 18; UNCLASSIFIED DRUG; UVOMORULIN;

ABDOMINAL PAIN; AMINO TERMINAL SEQUENCE; ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; BREAST CANCER; CANCER CELL; CANCER INVASION; CANCER THERAPY; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL TRANSFORMATION; CHEMOPROPHYLAXIS; CHROMOSOME 3; COLON CANCER; CROHN DISEASE; DIARRHEA; DIGESTIVE SYSTEM CANCER; DRUG ACTIVITY; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; EDEMA; ENTERITIS; ENZYME ACTIVATION; ENZYME INHIBITION; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; GASTROINTESTINAL TOXICITY; GENE DISRUPTION; GENE LOCATION; GLIOMA; HEART VENTRICLE HYPERTROPHY; HUMAN; INFLAMMATION; LIGAND BINDING; LIPOSARCOMA; LIVER TOXICITY; MACROPHAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OVARY POLYCYSTIC DISEASE; PROSTATE CANCER; PROSTATE CARCINOMA; PROTEIN EXPRESSION; RECEPTOR BINDING; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; SOLID TUMOR; STOMACH CANCER; THYROID CARCINOMA; TRANSCRIPTION INITIATION; TREATMENT RESPONSE; ULCERATIVE COLITIS; VOMITING;

EID: 72449162567     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2009/816957     Document Type: Article

References (106)

1. Issemann I., Green S., Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators Nature 1990 347 6294 645 650
2. Graves R. A., Tontonoz P., Spiegelman B. M., Analysis of a tissue-specific enhancer: ARF6 regulates adipogenic gene expression Molecular and Cellular Biology 1992 12 3 1202 1208
3. Zhu Y., Alvares K., Huang Q., Rao M. S., Reddy J. K., Cloning of a new member of the peroxisome proliferator-activated receptor gene family from mouse liver Journal of Biological Chemistry 1993 268 36 26817 26820
4. Willson T. M., Brown P. J., Sternbach D. D., The PPARs: fro orphan receptors to drug discovery Journal of Medicinal Chemistry 2000 43 527 550
5. Oliver W. R. Jr., Shenk J. L., Snaith M. R., Selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport Proceedings of the National Academy of Sciences of the United States of America 2001 98 5306 5311
6. Chawla A., Lee C.-H., Barak Y., PPAR is a very low-density lipoprotein sensor in macrophages Proceedings of the National Academy of Sciences of the United States of America 2003 100 3 1268 1273
7. Lim H., Dey S. K., PPAR functions as a prostacyclin receptor in blastocyst implantation Trends in Endocrinology and Metabolism 2000 11 4 137 142
8. Tan N. S., Michalik L., Noy N., Critical roles of PPAR / in keratinocyte response to inflammation Genes Development 2001 15 24 3263 3277
9. Peters J. M., Lee S. S. T., Li W., Growths, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor () Molecular and Cellular Biology 2000 20 14 5119 5128
10. Wang Y.-X., Lee C.-H., Tiep S., Peroxisome-proliferator-activated receptor activates fat metabolism to prevent obesity Cell 2003 113 2 159 170
11. Lefebvre A.-M., Paulweber B., Fajas L., Peroxisome proliferator-activated receptor gamma is induced during differentiation of colon epithelium cells Journal of Endocrinology 1999 162 3 331 340
12. Su W., Bush C. R., Necela B. M., Differential expression, distribution, and function of PPAR- in the proximal and distal colon Physiological Genomics 2007 30 3 342 353
13. Perry C. G., Petrie J. R., Insulin-sensitising agents: beyond thiazolidinediones Expert Opinion on Emerging Drugs 2002 7 1 165 174
14. Owen G. I., Zelent A., Origins and evolutionary diversification of the nuclear receptor superfamily Cellular and Molecular Life Sciences 2000 57 5 809 827
15. Nolte R. T., Wisely G. B., Westin S., Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor- Nature 1998 395 6698 137 143
16. Shiraki T., Kamiya N., Shiki S., Kodama T. S., Kakizuka A., Jingami H., / -unsaturated ketone is a core moiety of natural ligands for covalent binding to peroxisome proliferator-activated receptor Journal of Biological Chemistry 2005 280 14 14145 14153
17. Yki-Jrvinen H., Thiazolidinediones The New England Journal of Medicine 2004 351 11 1106 1118
18. Thompson E. A., PPAR physiology and pathology in gastrointestinal epithelial cells Molecules and Cells 2007 24 2 167 176
19. Greene M. E., Blumberg B., McBride O. W., Isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hematopoietic cells and chromosomal mapping Gene Expression 1995 4 4-5 281 299
20. Tontonoz P., Hu E., Graves R. A., Budavari A. I., Spiegelman B. M., mPPAR 2: tissue-specific regulator of an adipocyte enhancer Genes and Development 1994 8 10 1224 1234
21. Werman A., Hollenberg A., Solanes G., Bjrbk C., Vidal-Puig A. J., Flier J. S., Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor (PPAR ). Differential activity of PPAR 1 and -2 isoforms and influence of insulin Journal of Biological Chemistry 1997 272 32 20230 20235
22. Fajas L., Auboeuf D., Rasp E., The organization, promoter analysis, and expression of the human PPAR gene Journal of Biological Chemistry 1997 272 30 18779 18789
23. Mukherjee R., Jow L., Croston G. E., Paterniti J. R. Jr., Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPAR 2 versus PPAR 1 and activation with retinoid X receptor agonists and antagonists Journal of Biological Chemistry 1997 272 12 8071 8076
24. Vidal-Puig A. J., Considine R. V., Jimenez-Lian M., Peroxisome proliferator-activated receptor gene expression in human tissues: effects of obesity, weight loss, and regulation by insulin and glucocorticoids Journal of Clinical Investigation 1997 99 10 2416 2422
25. Zieleniak A., Wjcik M., Woniak L. A., Structure and physiological functions of the human peroxisome proliferator-activated receptor Archivum Immunologiae et Therapiae Experimentalis 2008 56 5 331 345
26. Heery D. M., Kalkhoven E., Hoare S., Parker M. G., A signature motif in transcriptional co-activators mediates binding to nuclear receptors Nature 1997 387 6634 733 736
27. McInerney E. M., Rose D. W., Flynn S. E., Determinants of coactivator LXXLL motif specificity in nuclear receptor transcriptional activation Genes Development 1998 12 21 3357 3368
28. Puigserver P., Wu Z., Park C. W., Graves R., Wright M., Spiegelman B. M., A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis Cell 1998 92 6 829 839
29. Adams M., Reginato M. J., Shao D., Lazar M. A., Chatterjee V. K., Transcriptional activation by peroxisome proliferator-activated receptor is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site Journal of Biological Chemistry 1997 272 8 5128 5132
30. Camp H. S., Tafuri S. R., Regulation of peroxisome proliferator-activated receptor activity by mitogen-activated protein kinase The Journal of Biological Chemistry 1997 272 10811 10816
31. Hu E., Kim J. B., Sarraf P., Spiegelman B. M., Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPAR Science 1996 274 5295 2100 2103
32. Lehmann J. M., Moore L. B., Smith-Oliver T. A., Wilkison W. O., Willson T. M., Kliewer S. A., An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor (PPAR ) Journal of Biological Chemistry 1995 270 22 12953 12956
33. Lehmann J. M., Lenhard J. M., Oliver B. B., Ringold G. M., Kliewer S. A., Peroxisome proliferator-activated receptors and are activated by indomethacin and other non-steroidal anti-inflammatory drugs Journal of Biological Chemistry 1997 272 6 3406 3410
34. Xu H. E., Lambert M. H., Montana V. G., Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors Proceedings of the National Academy of Sciences of the United States of America 2001 98 24 13919 13924
35. Chiarelli F., Di Marzio D., Peroxisome proliferator-activated receptor- agonists and diabetes: current evidence and future perspectives Vascular Health and Risk Management 2008 4 2 297 304
36. Parulkar A. A., Pendergrass M. L., Granda-Ayala R., Lee T. R., Fonseca V. A., Nonhypoglycemic effects of thiazolidinediones Annals of Internal Medicine 2001 134 1 61 71
37. Haffner S. M., Greenbeg A. S., Weston W. M., Effects of rosiglitazone treatment on non-traditional markers of cardiovascular disease in patients with type 2 diabetes mellitus Circulation 2002 106 679 684
38. Romualdi D., Guido M., Ciampelli M., Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome Human Reproduction 2003 18 6 1210 1218
39. Glintborg D., Stving R. K., Hagen C., Pioglitazone treatment increases spontaneous growth hormone (GH) secretion and stimulated GH levels in polycystic ovary syndrome The Journal of Clinical Endocrinology Metabolism 2005 90 10 5605 5612
40. Reifel-Miller A., Otto K., Hawkins E., A peroxisome proliferator- activated receptor / dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia Molecular Endocrinology 2005 19 6 1593 1605
41. Tong W.-G., Ding X.-Z., Hennig R., Leukotriene B4 receptor antagonist LY293111 inhibits proliferation and induces apoptosis in human pancreatic cancer cells Clinical Cancer Research 2002 8 10 3232 3242
42. Copland J. A., Kurakata S., Fujiwara K., A novel high affinity PPAR- agonist inhibits human anaplastic thyroid tumour growth Proceedings of the AACR Annual Meeting 2004 Orlando, Fla, USA. LB-17
43. Liu D.-C., Zang C.-B., Liu H.-Y., Possinger K., Fan S.-G., Elstner E., A novel PPAR alpha/gamma dual agonist inhibits cell growth and induces apoptosis in human glioblastoma T98G cells Acta Pharmacologica Sinica 2004 25 10 1312 1319
44. Schwartz G. K., Weitzman A., OReilly E., Phase I and pharmacokinetic study of LY293111, an orally bioavailable LTB4 receptor antagonist, in patients with advanced solid tumors Journal of Clinical Oncology 2005 23 23 5365 5373
45. Baetz T., Eisenhauer E., Siu L., A phase I study of oral LY293111 given daily in combination with irinotecan in patients with solid tumours Investigational New Drugs 2007 25 3 217 225
46. Kliewer S. A., Lenhard J. M., Willson T. M., Patel I., Morris D. C., Lehmann J. M., A prostaglandin J 2 metabolite binds peroxisome proliferator-activated receptor and promotes adipocyte differentiation Cell 1995 83 5 813 819
47. Forman B. M., Tontonoz P., Chen J., Brun R. P., Spiegelman B. M., Evans R. M., 15-deoxy- 12, 14 -prostaglandin J 2 is a ligand for the adipocyte determination factor PPAR Cell 1995 83 5 803 812
48. Kim E.-H., Surh Y.-J., The role of 15-deoxy- 12, 14 -prostaglandin J 2, an endogenous ligand of peroxisome proliferator-activated receptor, in tumor angiogenesis Biochemical Pharmacology 2008 76 11 1544 1553
49. Chen L., Bush C. R., Necela B. M., RS5444, a novel PPAR agonist, regulates aspects of the differentiated phenotype in nontransformed intestinal epithelial cells Molecular and Cellular Endocrinology 2006 251 1-2 17 32
50. Drori S., Girnun G. D., Tou L., Hic-5 regulates an epithelial program mediated by PPAR Genes Development 2005 19 3 362 375
51. Sarraf P., Mueller E., Smith W. M., Loss-of-function mutations in PPAR associated with human colon cancer Molecular Cell 1999 3 6 799 804
52. Ikezoe T., Miller C. W., Kawano S., Mutational analysis of the peroxisome proliferator-activated receptor in human malignancies Cancer Research 2001 61 13 5307 5310
53. Brockman J. A., Gupta R. A., Dubois R. N., Activation of PPAR leads to inhibition of anchorage-independent growth of human colorectal cancer cells Gastroenterology 1998 115 5 1049 1055
54. Sarraf P., Mueller E., Jones D., Differentiation and reversal of malignant changes in colon cancer through PPAR Nature Medicine 1998 4 9 1046 1052
55. Gupta R. A., Brockman J. A., Sarraf P., Willson T. M., DuBois R. N., Target genes of peroxisome proliferator-activated receptor in colorectal cancer cells Journal of Biological Chemistry 2001 276 32 29681 29687
56. Chen G. G., Lee J. F., Wang S. H., Chan U. P. F., Ip P. C., Lau W. Y., Apoptosis induced by activation of peroxisome-proliferator activated receptor-gamma is associated with Bcl-2 and NF- B in human colon cancer Life Sciences 2002 70 22 2631 2646
57. Shimada T., Kojima K., Yoshiura K., Hiraishi H., Terano A., Characteristics of the peroxisome proliferator activated receptor (PPAR ) ligand induced apoptosis in colon cancer cells Gut 2002 50 5 658 664
58. Gupta R. A., Sarraf P., Mueller E., Peroxisome proliferator-activated receptor -mediated differentiation: a mutation in colon cancer cells reveals divergent and cell type-specific mechanisms Journal of Biological Chemistry 2003 278 25 22669 22677
59. Yoshizumi T., Ohta T., Ninomiya I., Thiazolidinedione, a peroxisome proliferator-activated receptor-gamma ligand, inhibits growth and metastasis of HT-29 human colon cancer cells through differentiation-promoting effects International Journal of Oncology 2004 25 3 631 639
60. Qiao L., Dai Y., Gu Q., Down-regulation of X-linked inhibitor of apoptosis synergistically enhanced peroxisome proliferator-activated receptor ligand-induced growth inhibition in colon cancer Molecular Cancer Therapeutics 2008 7 7 2203 2211
61. Girnun G. D., Smith W. M., Drori S., APC-dependent suppression of colon carcinogenesis by PPAR Proceedings of the National Academy of Sciences of the United States of America 2002 99 21 13771 13776
62. Lu J., Imamura K., Nomura S., Chemopreventive effect of peroxisome proliferator-activated receptor on gastric carcinogenesis in mice Cancer Research 2005 65 11 4769 4774
63. Dai Y., Qiao L., Kwok W. C., Peroxisome proliferator-activated receptor- contributes to the inhibitory effects of embelin on colon carcinogenesis Cancer Research 2009 69 11 4776 4783
64. McAlpine C. A., Barak Y., Matise I., Cormier R. T., Intestinal-specific PPAR deficiency enhances tumorigenesis in Apc Min / + mice International Journal of Cancer 2006 119 10 2339 2346
65. Niho N., Takahashi M., Kitamura T., Concomitant suppression of hyperlipidemia and intestinal polyp formation in Apc-deficient mice by peroxisome proliferator-activated receptor ligands Cancer Research 2003 63 18 6090 6095
66. Niho N., Takahashi M., Shoji Y., Dose-dependent suppression of hyperlipidemia and intestinal polyp formation in Min mice by pioglitazone, a PPAR ligand Cancer Science 2003 94 11 960 964
67. Osawa E., Nakajima A., Wada K., Peroxisome proliferator-activated receptor ligands suppress colon carcinogenesis induced by azoxymethane in mice Gastroenterology 2003 124 2 361 367
68. Kohno H., Yoshitani S., Takashima S., Troglitazone, a ligand for peroxisome proliferator-activated receptor, inhibits chemically-induced aberrant crypt foci in rats Japanese Journal of Cancer Research 2001 92 4 396 403 (Pubitemid 32427775)
69. Tanaka T., Kohno H., Yoshitani S.-I., Ligands for peroxisome proliferator-activated receptors and inhibit chemically induced colitis and formation of aberrant crypt foci in rats Cancer Research 2001 61 6 2424 2428
70. Fajas L., Egler V., Reiter R., Miard S., Lefebvre A.-M., Auwerx J., PPAR controls cell proliferation and apoptosis in an RB-dependent manner Oncogene 2003 22 27 4186 4193
71. Huang J.-W., Shiau C.-W., Yang Y.-T., Peroxisome proliferator-activated receptor -independent ablation of cyclin D1 by thiazolidinediones and their derivatives in breast cancer cells Molecular Pharmacology 2005 67 4 1342 1348
72. Shiau C.-W., Yang C.-C., Kulp S. K., Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPAR Cancer Research 2005 65 4 1561 1569
73. Elnemr A., Ohta T., Iwata K., PPARgamma ligand (thiazolidinedione) induces growth arrest and differentiation markers of human pancreatic cancer cells International Journal of Oncology 2000 17 6 1157 1164
74. Koga H., Sakisaka S., Harada M., Involvement of p21WAF1/Cip1, p27Kip1, and p18INK4c in troglitazone-induced cell-cycle arrest in human hepatoma cell lines Hepatology 2001 33 5 1087 1097
75. Chen F., Harrison L. E., Ciglitazone-induced cellular anti-proliferation increases p27 kip1 protein levels through both increased transcriptional activity and inhibition of proteasome degradation Cellular Signalling 2005 17 7 809 816
76. Qiao L., Dai Y., Gu Q., Loss of XIAP sensitizes colon cancer cells to PPAR independent antitumor effects of troglitazone and 15-PG J 2 Cancer Letters 2008 268 2 260 271
77. Dai Y., Qiao L., Kwok W. C., Loss of XIAP sensitizes rosiglitazone- induced growth inhibition of colon cancer in vivo International Journal of Cancer 2008 122 12 2858 2863
78. Kim Y., Suh N., Sporn M., Reed J. C., An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis Journal of Biological Chemistry 2002 277 25 22320 22329
79. Saez E., Tontonoz P., Nelson M. C., Activators of the nuclear receptor PPAR enhance colon polyp formation Nature Medicine 1998 4 9 1058 1061
80. Yang K., Fan K.-H., Lamprecht S. A., Peroxisome proliferator-activated receptor agonist troglitazone induces colon tumors in normal C57BL/6J mice and enhances colonic carcinogenesis in A p c 1638 N / + M l h 1 + /-double mutant mice International Journal of Cancer 2005 116 4 495 499
81. Palakurthi S. S., Aktas H., Grubissich L. M., Mortensen R. M., Halperin J. A., Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor and mediated by inhibition of translation initiation Cancer Research 2001 61 16 6213 6218
82. Baek S. J., Wilson L. C., Hsi L. C., Eling T. E., Troglitazone, a peroxisome proliferator-activated receptor (PPAR ) ligand, selectively induces the early growth response-1 gene independently of PPAR : a novel mechanism for its anti-tumorigenic activity Journal of Biological Chemistry 2003 278 8 5845 5853
83. Akasaki Y., Liu G., Matundan H. H., A peroxisome proliferator-activated receptor- agonist, troglitazone, facilitates caspase-8 and -9 activities by increasing the enzymatic activity of protein-tyrosine phosphatase-1B on human glioma cells Journal of Biological Chemistry 2006 281 10 6165 6174
84. Li X., Yang X., Xu Y., Troglitazone inhibits cell proliferation by attenuation of epidermal growth factor receptor signaling independent of peroxisome proliferator-activated receptor Cell Research 2009 19 6 720 732
85. Bassaganya-Riera J., Carter A. B., Misyak S. A., Hontecillas R., Dietary modulation of inflammation-induced colorectal cancer through PPAR PPAR Research 2009 2009 9
86. Mir-Madjlessi S. H., Farmer R. G., Easley K. A., Beck G. J., Colorectal and extracolonic malignancy in ulcerative colitis Cancer 1986 58 7 1569 1574
87. Ekbom A., Helmick C., Zack M., Adami H.-O., Increased risk of large-bowel cancer in Crohns disease with colonic involvement The Lancet 1990 336 8711 357 359
88. Dubuquoy L., Rousseaux C., Thuru X., PPAR as a new therapeutic target in inflammatory bowel diseases Gut 2006 55 9 1341 1349
89. Ricote M., Li A. C., Willson T. M., Kelly C. J., Glass C. K., The peroxisome proliferator-activated receptor- is a negative regulator of macrophage activation Nature 1998 391 6662 79 82
90. Shah Y. M., Morimura K., Gonzalez F. J., Expression of peroxisome proliferator-activated receptor- in macrophage suppresses experimentally induced colitis American Journal of Physiology 2007 292 2 G657 G666
91. Watanabe N., Ikuta K., Okazaki K., Elimination of local macrophages in intestine prevents chronic colitis in interleukin-10-deficient mice Digestive Diseases and Sciences 2003 48 2 408 414
92. Rousseaux C., Lefebvre B., Dubuquoy L., Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator- activated receptor- Journal of Experimental Medicine 2005 201 8 1205 1215
93. Ramakers J. D., Verstege M. I., Thuijls G., Te Velde A. A., Mensink R. P., Plat J., The PPAR agonist rosiglitazone impairs colonic inflammation in mice with experimental colitis Journal of Clinical Immunology 2007 27 3 275 283
94. Lytle C., Tod T. J., Vo K. T., Lee J. W., Atkinson R. D., Straus D. S., The peroxisome proliferator-activated receptor ligand rosiglitazone delays the onset of inflammatory bowel disease in mice with interleukin 10 deficiency Inflammatory Bowel Diseases 2005 11 3 231 243
95. Lewis J. D., Lichtenstein G. R., Stein R. B., An open-label trial of the PPAR ligand rosiglitazone for active ulcerative colitis American Journal of Gastroenterology 2001 96 12 3323 3328
96. Kurumbail R. G., Stevens A. M., Gierse J. K., Structural basis for selective inhibition of cyciooxygenase-2 by anti-inflammatory agents Nature 1996 384 6610 644 648
97. Baron J. A., Cole B. F., Sandler R. S., A randomized trial of aspirin to prevent colorectal adenomas The New England Journal of Medicine 2003 348 10 891 899
98. Fan X. M., Jiang X. H., Gu Q., Inhibition of Akt/PKB by a COX-2 inhibitor induces apoptosis in gastric cancer cells Digestion 2006 73 2-3 75 83
99. Zhang M., Deng C., Zheng J., Xia J., Sheng D., Curcumin inhibits trinitrobenzene sulphonic acid-induced colitis in rats by activation of peroxisome proliferator-activated receptor gamma International Immunopharmacology 2006 6 8 1233 1242
100. Felts A. S., Ji C., Stafford J. B., Desmethyl derivatives of indomethacin and sulindac as probes for cyclooxygenase-dependent biology ACS Chemical Biology 2007 2 7 479 483
101. Sun W.-H., Chen G.-S., Ou X.-L., Inhibition of COX-2 and activation of peroxisome proliferator-activated receptor synergistically inhibits proliferation and induces apoptosis of human pancreatic carcinoma cells Cancer Letters 2009 275 2 247 255
102. Schrder O., Yudina Y., Sabirsh A., Zahn N., Haeggstrm J. Z., Stein J., 15-deoxy- 12, 14 -prostaglandin J 2 inhibits the expression of microsomal prostaglandin E synthase type 2 in colon cancer cells Journal of Lipid Research 2006 47 5 1071 1080
103. Vandoros G. P., Konstantinopoulos P. A., Sotiropoulou-Bonikou G., PPAR-gamma is expressed and NF- B pathway is activated and correlates positively with COX-2 expression in stromal myofibroblasts surrounding colon adenocarcinomas Journal of Cancer Research and Clinical Oncology 2006 132 2 76 84
104. Guarino M., Epithelial-mesenchymal transition and tumour invasion International Journal of Biochemistry and Cell Biology 2007 39 12 2153 2160
105. Chen L., Necela B. M., Su W., Peroxisome proliferator-activated receptor promotes epithelial to mesenchymal transformation by Rho GTPase-dependent activation of ERK1/2 Journal of Biological Chemistry 2006 281 34 24575 24587
106. Margeli A., Kouraklis G., Theocharis S., Peroxisome proliferator activated receptor- (PPAR- ) ligands and angiogenesis Angiogenesis 2003 6 3 165 169 (Pubitemid 38506661)